Tags

Type your tag names separated by a space and hit enter

Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
Ann Intern Med 1991; 114(7):539-44AIM

Abstract

OBJECTIVE

To test the hypothesis that propafenone, administered orally, prevents symptomatic paroxysmal supraventricular arrhythmias.

DESIGN

a 6-month, open-label, dose-finding phase followed by a randomized, double-blind, placebo-controlled, crossover phase, with each treatment period lasting up to 60 days.

SETTING

An outpatient clinic.

PATIENTS

Thirty-three patients with either paroxysmal supraventricular tachycardia (n = 16) or paroxysmal atrial fibrillation (n = 17) were enrolled. Their arrhythmias were documented by electrocardiogram before enrollment. Twenty-three patients (14 with paroxysmal supraventricular tachycardia and 9 with paroxysmal atrial fibrillation) were randomized and the data obtained from these patients were used in the efficacy analysis.

INTERVENTION

Propafenone (300 mg three times daily in 19 patients, 300 mg twice daily in 3 patients, and 150 mg twice daily in 1 patient) and matching placebo tablets were administered in a randomized sequence.

MEASUREMENTS

Symptomatic arrhythmia was documented by telephone transmission of the electrocardiogram.

MAIN RESULTS

The time to first recurrence was prolonged for the overall group of 23 patients while they received propafenone (P = 0.004). The recurrence rate of arrhythmia during treatment with propafenone was estimated to be approximately one fifth of the recurrence rate during treatment with placebo.

CONCLUSIONS

Propafenone is effective in reducing symptomatic paroxysmal supraventricular arrhythmias.

Authors+Show Affiliations

Duke University Medical Center, Durham, North Carolina.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

2001087

Citation

Pritchett, E L., et al. "Propafenone Treatment of Symptomatic Paroxysmal Supraventricular Arrhythmias. a Randomized, Placebo-controlled, Crossover Trial in Patients Tolerating Oral Therapy." Annals of Internal Medicine, vol. 114, no. 7, 1991, pp. 539-44.
Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114(7):539-44.
Pritchett, E. L., McCarthy, E. A., & Wilkinson, W. E. (1991). Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Annals of Internal Medicine, 114(7), pp. 539-44.
Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone Treatment of Symptomatic Paroxysmal Supraventricular Arrhythmias. a Randomized, Placebo-controlled, Crossover Trial in Patients Tolerating Oral Therapy. Ann Intern Med. 1991 Apr 1;114(7):539-44. PubMed PMID: 2001087.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. AU - Pritchett,E L, AU - McCarthy,E A, AU - Wilkinson,W E, PY - 1991/4/1/pubmed PY - 1991/4/1/medline PY - 1991/4/1/entrez SP - 539 EP - 44 JF - Annals of internal medicine JO - Ann. Intern. Med. VL - 114 IS - 7 N2 - OBJECTIVE: To test the hypothesis that propafenone, administered orally, prevents symptomatic paroxysmal supraventricular arrhythmias. DESIGN: a 6-month, open-label, dose-finding phase followed by a randomized, double-blind, placebo-controlled, crossover phase, with each treatment period lasting up to 60 days. SETTING: An outpatient clinic. PATIENTS: Thirty-three patients with either paroxysmal supraventricular tachycardia (n = 16) or paroxysmal atrial fibrillation (n = 17) were enrolled. Their arrhythmias were documented by electrocardiogram before enrollment. Twenty-three patients (14 with paroxysmal supraventricular tachycardia and 9 with paroxysmal atrial fibrillation) were randomized and the data obtained from these patients were used in the efficacy analysis. INTERVENTION: Propafenone (300 mg three times daily in 19 patients, 300 mg twice daily in 3 patients, and 150 mg twice daily in 1 patient) and matching placebo tablets were administered in a randomized sequence. MEASUREMENTS: Symptomatic arrhythmia was documented by telephone transmission of the electrocardiogram. MAIN RESULTS: The time to first recurrence was prolonged for the overall group of 23 patients while they received propafenone (P = 0.004). The recurrence rate of arrhythmia during treatment with propafenone was estimated to be approximately one fifth of the recurrence rate during treatment with placebo. CONCLUSIONS: Propafenone is effective in reducing symptomatic paroxysmal supraventricular arrhythmias. SN - 0003-4819 UR - https://www.unboundmedicine.com/medline/citation/2001087/Propafenone_treatment_of_symptomatic_paroxysmal_supraventricular_arrhythmias__A_randomized_placebo_controlled_crossover_trial_in_patients_tolerating_oral_therapy_ L2 - https://www.annals.org/article.aspx?volume=114&issue=7&page=539 DB - PRIME DP - Unbound Medicine ER -